A 4-Part, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult, Elderly and Japanese Subjects, and the Pharmacodynamics in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2017
At a glance
- Drugs E 2027 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Eisai Inc
- 23 Dec 2016 Status changed from recruiting to completed.
- 12 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
- 12 May 2016 Planned primary completion date changed from 1 May 2016 to 1 Jun 2016.